Condition: Iron Metabolism Disorders · Calcium Phosphate Metabolism · Hepatic Metabolic Disorders · Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure. The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients. The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.
This description comes directly from the study's public registry record.
Jean-François Oudet · 0683346567 · jeanfrancois.oudet@free.fr
Marie-Hélène Barba · mh.barba@ecten.eu
Always discuss trial participation with your own doctor first.
| Hôpital Privé Claude Galien | Quincy-sous-Sénart, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05586867